Additional funding for biomedical research at the state and federal level will help us discover new and more effective treatments for breast cancer so that we can save more lives. That’s because groundbreaking research is conducted at the National Institutes of Health (NIH), the Department of Defense (DOD) and through state agencies, and more funding for the agencies’ biomedical research will lead to more and better treatment options.
Not all populations are represented in clinical trials, likely because trials are not offered to patients in an inclusive and equitable way. Educating patients about clinical research options, breaking down barriers to trial participation, and inviting them to participate would help include people from all ages, genders and ethnicities and further our ability to develop therapies that are effective in all populations. To make it possible for more diverse populations to participate, policies must require coverage of indirect costs to patients to facilitate participation (e.g., transportation, childcare, clinical navigation)
Accelerating Research Priorities
- Increase biomedical research funding
- Increase clinical trial diversity, including by requiring coverage of indirect costs to patient to facilitate participation (e.g., transportation, childcare, clinical navigation)